August 7, 2021
Outcomes for High-Risk MDS Patients Undergoing Transplant vs Standard Non-Transplant Therapies
Outcomes for High-Risk MDS Patients Undergoing Transplant vs Standard Non-Transplant Therapies
This webinar will provide an overview of the role of allogeneic hematopoietic cell transplantation (alloHCT) for high-risk MDS patients. Standard therapies for patients with MDS including hypomethylating agents (HMAs) and a variety of novel agents outside of allogeneic HCT will be discussed.
Speaker
EW
Erica D. Warlick, MD
Our Supporters
Thank you to Bristol-Myers Squibb, Novartis, Jazz Pharmaceuticals, Takeda Oncology, Acceleron, and Gamida Cell for supporting this initiative.
